Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,018 recalls, newest first

Class I · High risk

Walgreens

Microbial contamination of non-sterile products.

Terminated Microbial contamination Vi-Jon, LLC NDC 0363-7162-38 D-1510-2022
Class I · High risk

Walgreens

Microbial contamination of non-sterile products.

Terminated Microbial contamination Vi-Jon, LLC NDC 0363-8166-38 D-1509-2022
Class I · High risk

Swan

Microbial contamination of non-sterile products.

Terminated Microbial contamination Vi-Jon, LLC NDC 0869-0166-38 D-1507-2022
Class I · High risk

Rexall

Microbial contamination of non-sterile products.

Terminated Microbial contamination Vi-Jon, LLC NDC 55910-183-38 D-1506-2022
Class I · High risk

meijer

Microbial contamination of non-sterile products.

Terminated Microbial contamination Vi-Jon, LLC NDC 41250-708-38 D-1504-2022
Class I · High risk

Kroger

Microbial contamination of non-sterile products.

Terminated Microbial contamination Vi-Jon, LLC NDC 30142-899-38 D-1503-2022
Class II · Moderate risk

Avant Foaming Hand Sanitizer

CGMP Deviations: product manufactured using deionized water from a system lacking appropriate microbial control post deionization.

Terminated Microbial contamination Aire-Master of America Inc D-1355-2022
Class II · Moderate risk

Difluprednate Ophthalmic Emulsion

Lack of Assurance of Sterility: customer complaint for defective container where breakage of the protective cap exposes tip of eye drop which could compromise sterility.

Terminated Sterility / contamination Cipla NDC 69097-341-35 D-1283-2022
Class II · Moderate risk

Lorazepam Injection

Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples.

Terminated Impurity / degradation Hikma Pharmaceuticals USA Inc. NDC 0641-6045-25 D-1310-2022
Class II · Moderate risk

Lorazepam Injection

Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples.

Terminated Impurity / degradation Hikma Pharmaceuticals USA Inc. NDC 0641-6048-25 D-1309-2022
Class II · Moderate risk

Ativan Injection

Failed Impurities/Degradation Specifications: Out-of-specification results observed for total related compounds during testing of retain samples.

Terminated Impurity / degradation Hikma Pharmaceuticals USA Inc. NDC 0641-6001-25 D-1308-2022

Recalls by year